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Coenzyme Q10 is a mobile lipophilic electron carrier located in the inner mitochondrial membrane. Defects of coenzyme Q10 biosyn-
thesis represent one of the few treatable mitochondrial diseases. We genotyped a patient with primary coenzyme Q10 deﬁciency who
presented with neonatal lactic acidosis and later developed multisytem disease including intractable seizures, global developmental
delay, hypertrophic cardiomyopathy, and renal tubular dysfunction. Cultured skin ﬁbroblasts from the patient had a coenzyme Q10
biosynthetic rate of 11% of normal controls and accumulated an abnormal metabolite that we believe to be a biosynthetic intermediate.
In view of the rarity of coenzyme Q10 deﬁciency, we hypothesized that the disease-causing gene might lie in a region of ancestral homo-
zygosity by descent. Data from an Illumina HumanHap550 array were analyzed with BeadStudio software. Sixteen regions of homozy-
gosity >1.5 Mb were identiﬁed in the affected infant. Two of these regions included the loci of two of 16 candidate genes implicated in
human coenzyme Q10 biosynthesis. Sequence analysis demonstrated a homozygous stop mutation affecting a highly conserved residue
of COQ9, leading to the truncation of 75 amino acids. Site-directed mutagenesis targeting the equivalent residue in the yeast Saccharo-
myces cerevisiae abolished respiratory growth.Introduction
Coenzyme Q10, or ubiquinone, is a lipophilic molecule
located in the inner mitochondrial membrane, where it
functions to shuttle electrons from complexes I (NADH:
ubiquinone reductase, EC 1.6.5.3) and II (succinate:
ubiquinone reductase, EC 1.3.5.1) to complex III (ubiqui-
nol:cytochrome-c reductase, EC 1.10.2.2) in the respiratory
chain. Reduced coenzyme Q10 (ubiquinol) also has an
important antioxidant role. Other functions of coenzyme
Q10 include electron transfer in extramitochondrial elec-
tron transport systems (for example, in plasmamembranes
and lysosomes) and regulation of mitochondrial perme-
ability transition pores.1
Primary coenzymeQ10 deﬁciency (MIM 607426) is reces-
sively inherited and constitutes a rare but important
subgroup of mitochondrial respiratory chain disease,
because it is potentially treatable with exogenous coen-
zyme Q10. Heterogeneous clinical phenotypes have been
reported in association with coenzyme Q10 deﬁciency,
including recurrent rhabdomyolysis with seizures,2,3
multisystem disorder of infancy with prominent nephrop-
athy,4,5 ataxia with or without seizures,6 Leigh syndrome,7
and pure myopathy.8 Secondary deﬁciency of coenzyme
Q10 has been implicated in the pathophysiology of statin
myopathy, anthracycline toxicity, and Parkinson disease,although the relative contribution of coenzyme Q10 deﬁ-
ciency in these disease processes is debated.9,10
Deﬁciency of coenzyme Q10 is suspected when activities
of respiratory chain complexes IþIII and/or IIþIII are deﬁ-
cient when assayed together (because these assays require
the presence of endogenous coenzyme Q10), but activities
of individual respiratory chain complexes I, II, and III are
all normal when assayed separately (because these assays
are independent of coenzyme Q10). The diagnosis is
conﬁrmed by measurement of coenzyme Q10 in muscle.
PlasmacoenzymeQ10 level is anunreliable indicatorof total
body coenzyme Q10 status, because the former is known to
ﬂuctuate with plasma lipid levels.10 However, there is some
preliminary evidence that peripheral blood mononuclear
cell coenzyme Q10 levels are more closely correlated to
muscle coenzymeQ10 levels thanareplasma levels, sowhite
blood cell coenzyme Q10 estimation may be a useful
primary screening tool for this group of disorders.11
Coenzyme Q10 is a member of a homologous family of
ubiquinones that comprise a benzoquinone ring and
a polyprenyl ‘‘tail’’ that anchors the molecule to lipid
membranes. The numerical subscript used in coenzyme
Q nomenclature refers to the number of isoprenyl units
in the tail of the molecule. In humans coenzyme Q10
predominates, whereas rodents primarily use coenzyme
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the major isoform. Although the biosynthetic pathway
of coenzyme Q10 has not been completely elucidated in
humans, it is known that the ring is derived from tyrosine
or phenylalanine, whereas the mevalonate pathway gener-
ates the decaprenyl tail (Figure 1). The intermediates
4-hydroxybenzoate and decaprenyl diphosphate are then
condensed by 4-hydroxybenzoate: polyprenyl transferase,
encoded by COQ2 (MIM 609825).1 There are thought to be
eight subsequent steps that modify the 6-carbon ring and
its side chains to form the functional coenzyme Q10 mole-
cule (Figure 1).
Genes involved in the biosynthesis of coenzyme Q10
have been characterized in lower organisms (including
bacteria, yeast, and nematodes), and the human homologs
of 16 of these genes have been identiﬁed (Table 1).12
Recently, this has allowed the genetic basis of primary
coenzyme Q10 deﬁciency to be determined in some
patients. Mutations in four genes have been reported, in
association with a range of clinical phenotypes: mutations
in COQ2, PDSS1 (MIM 607429), and PDSS2 (MIM 610564)
have been reported in infantile encephalomyopathies,13–16
whereas more recently mutations in CABC1 (MIM 606980)
Figure 1. Biosynthetic Pathway of
Coenzyme Q10
have been associated with juvenile-
onset ataxia often accompanied by
seizures.17,18 In other patients, the
coenzyme Q10 deﬁciency has been
shown to be secondary to other
genetic defects: aprataxin mutations
in an ataxic form of the disease (MIM
606350)19,20 and mutations in the
ETFDH gene (MIM 231657) (which is
mutated in multiple acyl CoA dehy-
drogenase deﬁciency or glutaric acidu-
ria type II [MIM 231680]) in patients
with the myopathic presentation of
coenzyme Q10 deﬁciency.
21
We now show that a mutation in
COQ9, a biosynthetic gene not previ-
ously associated with human disease,
is a novel cause of coenzyme Q10
deﬁciency. We report a homozygous
nonsense mutation in the COQ9
gene in a patient with neonatal-
onset lactic acidosis and multisystem
disease. To our knowledge, this is the
ﬁrst report of human coenzyme Q10
deﬁciency resulting from a mutation
in COQ9. It is important to identify
the genetic basis of coenzyme Q10
deﬁciency because more rapid diag-
nosis allows prompt treatment with
exogenous coenzyme Q10 and may
improve the outcome of these otherwise devastating and
potentially fatal disorders.22
Subjects and Methods
Patient
The clinical details of this patient have previously been reported.5 In
brief, the patient was the seventh child of healthy apparently unre-
latedparentsof Pakistani originwhohadﬁveotherhealthy children.
An older sister had died on day one of life with a disorder including
seizures, acidosis, and aminoaciduria. No diagnosis wasmade in the
older sister. The patient presented at 6 hr of age with poor feeding,
hypothermia, increased tone, and lactic acidosis (plasma lactate
19.4 mmol/l, reference range 0.9–1.9). He developed an intractable
seizure disorder and was subsequently shown to have severe
global developmental delay, with cerebral and cerebellar atrophy
on magnetic resonance imaging of the brain. There was also left
ventricular hypertrophy and renal tubular dysfunction. Open
musclebiopsyperformedat10monthsshowedtypeIIBﬁberatrophy
and lipid accumulation on histological examination and a severe
biochemical defect of complexes IIþIII with normal activities of
complexes II and III when assayed separately. HPLC assay conﬁrmed
severe deﬁciency of coenzyme Q10 in skeletal muscle (Table 2).
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Coenzyme Q10 replacement therapy was started at 11.5 months
of age, initially at a dose of 60 mg/day in three divided doses, and
increasing after 6 days to 300mg/day, again in three divided doses.
This dose was continued until the patient’s death at 2 years of age.
Although the plasma lactate appeared to drop after commencing
coenzyme Q10 treatment (initially from 7.6 mmol/L to 4.4 mmol/L
11 days after starting treatment, and then to 2.5–2.9 mmol/L after
4months), there was no associated clinical response. Seizures resis-
tant toquadruple anticonvulsant therapycontinuedandwere asso-
ciated with severe global developmental delay, microcephaly, and
dystonia. Renal tubular function had already improved prior to
starting coenzyme Q10, but the cardiomyopathy continued to
Table 1. Genes Implicated in the Biosynthesis of Human
Coenzyme Q10
Gene
Chromosomal
Location Protein
PDSS1 10p12.1 decaprenyl-diphosphate synthase subunit 1
PDSS2 6q21 decaprenyl-diphosphate synthase subunit 2
COQ2 4q21.23 4-hydroxybenzoate polyprenyltransferase
COQ3 6q16.3 hexaprenyldihydroxybenzoate
methyltransferase
COQ4 9q34.11 ubiquinone biosynthesis
protein COQ4 homolog
COQ5 12q24.31 ubiquinone biosynthesis
methyltransferase COQ5
COQ6 14q24.3 ubiquinone biosynthesis
monooxygenase COQ6
COQ7 16p12.3 ubiquinone biosynthesis protein
COQ7 homolog
CABC1 1q42.13 chaperone-activity of bc1 complex-like,
mitochondrial precursor (Chaperone-
ABC1-like) (aarF domain-containing
protein kinase 3)
COQ9 16q13 ubiquinone biosynthesis protein COQ9
COQ10A 12q13.2 protein COQ10 A
COQ10B 2q33.1 protein COQ10 B
ADCK1 14q24.3 uncharacterized aarF domain-containing
protein kinase 1
ADCK2 7q34 uncharacterized aarF domain-containing
protein kinase 2
ADCK4 19q13.2 uncharacterized aarF domain-containing
protein kinase 4
ADCK5 8q24.3 uncharacterized aarF domain-containing
protein kinase 5
Table 2. Coenzyme Q10 Levels in Muscle and Cultured Skin
Fibroblasts and Biosynthesis of CoQ10 in Cultured Skin
Fibroblasts
Coenzyme Q10 Levels Patient Mean Control5 SD
Muscle
(pmol/mg protein)
37 2415 95
(range 140–580, n ¼ 26)
Fibroblasts
(pmol/mg protein)
25.3 625 14
(range 39–75, n ¼ 5)
Fibroblasts
(ng/mg protein)
10.4 585 10
(range 41–72, n ¼ 15)
Biosynthesis of CoQ10
in fibroblasts
(Q10 DPM/mg protein/day)
304, 480 34605 505
(range 3022–4207, n ¼ 6)560 The American Journal of Human Genetics 84, 558–566, May 15worsen despite treatment. The patient died just after his second
birthday after an intercurrent chest infection.
Muscle and skin biopsies were performed after obtaining
informed parental consent, and the study was approved by the
Great Ormond Street Hospital for Children NHS Trust and Insti-
tute of Child Health Local Research Ethics Committee.
Determination of Coenzyme Q10 Levels and
Biosynthetic Activity in Cultured Skin Fibroblasts
After lipid extraction from homogenized cultured skin ﬁbroblasts,
coenzyme Q10 levels were determined via reversed-phase HPLC
coupled to UV detection at 275 nm11 or electrochemical (EC)
detection.14 Rates of coenzyme Q10 biosynthesis were determined
by measurement of incorporation of 14C into coenzyme Q10 after
culturing skin ﬁbroblasts in 14C-radiolabelled 4-hydroxybenzoate
for 24 hr, as previously described.14
SNP Analysis
High-density genome-wide SNP genotyping was performed by
hybridizing total genomic DNA extracted from patient ﬁbroblasts
on aHumanHap550 array according to themanufacturer’s instruc-
tions (Illumina Inc.). SNP data was analyzed with BeadStudio v3
(Illumina Inc.) to search for regions of homozygosity.23
Candidate Gene Sequence Analysis
Exons and exon-intron boundaries of the coding sequence of two
candidate genes (CABC1 and COQ9) located within regions of
homozygosity were PCR ampliﬁed from genomic DNA (primers
for COQ9 are listed in Supplemental Data available online; primers
for CABC1 are available on request). The amplicons were puriﬁed
and subsequently sequenced bidirectionally, with the ABI BigDye
Terminator 3.1 system (Applied Biosystems), on a MegaBace DNA
sequencer. Sequence data were analyzed with Sequencher 4.6 soft-
ware (Gene Codes).
Reverse Transcriptase-PCR Analysis of COQ9
from Fibroblasts
RNA was extracted from ﬁbroblast cultures from the patient and
three controls with the RNeasy Mini kit and QIAshredder columns
(QIAGEN) according to themanufacturer’s instructions. cDNAwas
generated with the SuperScript III reverse transcriptase kit (Invitro-
gen) as per the supplied protocol. Two independent RNA extrac-
tions were performed. PCR was performed with primers speciﬁc
for cDNA for COQ9 (in exon 1 and the 30-UTR) and exon 4 of
RPL19 (a housekeeping gene encoding the 60S ribosomal protein
L19); primer sequences are available on request. Amplicons were
visualized on a 1.5% agarose gel with ethidium bromide. PCR reac-
tions were performed three times with cDNA generated from the
two independent extractions.
Modeling of COQ9 Structure
Candidate templates for the COQ9 sequence (Uniprot O75208)
were found with the 3DJury metaserver.24 COQ9 was found to be
distantly related to a large number of transcriptional regulators
from Streptomyces species. Two templates, PDB codes 3c07 and
2qib, were chosen for modeling, the latter in order to fully cover
the C terminus, whichwas uniquely aligned by this template. Resi-
dues 1–94 from the sequence were not matched by any template
and were not modeled; the Disopred method25 predicts much
of this region to be disordered. All of the templates were dimeric
according to PQS,26 so we additionally built dimeric models for, 2009
assessment. Initial alignments from 3DJury were manually reﬁned
to avoid indels within elements of secondary structure. Models
were generated with MODELER27 and assessed for hydrophobic
packing with SolvX28 and other model quality parameters with
MODCHECK-HD.29 The best model was selected with these scores
and rmsdeviation fromthe template structures. Side-chainpacking
in the ﬁnal model was optimized with SCWRL.30
Yeast Studies
The yeast COQ9 gene was ampliﬁed by PCR from genomic DNA of
strain W303-1B. The human COQ9 gene was ampliﬁed by PCR of
cDNAs that were kindly provided by E. Jacquet (ISCN, CNRS, Gif-
sur-Yvette, France) and were obtained by reverse transcription of
mRNAs extracted from human cell lines. The COQ9 genes were
cloned into a multicopy vector carrying the LEU2 marker and
placed under the control of a constitutive promoter (PGK). After
checking the sequence of the insert, the plasmids were used for
transformationof aDcoq9 yeast (W303-1AMATa, ade2-1, his3-1,15,
leu2-3,112, trp1-1, ura3-1, coq9::URA3), kindly given byA. Tzagoloff
(Columbia University, NY). Leuþ transformants were selected on
synthetic minimum medium, with a fermentable carbon source
(minimum medium: 0.7% yeast nitrogen base, 3% glucose, CSM
supplement minus leucine). Respiratory growth was checked on
respiratory medium (YPG: 1% yeast extract, 2% peptone, 3% glyc-
erol). Site-directed mutagenesis was performed with the Quick-
change Site-Directed Mutagenesis Kit (Stratagene) according to
the manufacturer’s recommendations.
Results
Biosynthesis of Coenzyme Q10 in Cultured Skin
Fibroblasts
In agreement with previous assays of mitochondrial respi-
ratory enzyme activities and coenzyme Q10 levels in
muscle,5 HPLC analysis demonstrated low levels of coen-
zyme Q10 in cultured skin ﬁbroblasts from the patient
compared to controls (Table 2) and also revealed a second
peak with a slightly shorter retention time than coenzyme
Q10. This might represent abnormal accumulation of a
biosynthetic intermediate (Figure 2). The rate of biosyn-
thesis of coenzyme Q10, determined with
14C-4-hydroxy-
benzoate, in cultured skin ﬁbroblasts from the patient
was 11% of the mean control activity (Table 2), conﬁrming
the presence of a severe primary defect of coenzyme Q10
biosynthesis in this patient.
SNP Analysis
Analysis of SNP data revealed 16 regions of homozygosity
of between 1.5 and 16.8 Mb, of which ﬁve were greater
than 10 Mb in length (Table 3). The longest region of
homozygosity was observed on chromosome 17, but did
not contain any candidate genes known to be involved
in the biosynthesis of coenzyme Q10. The third and fourth
largest regions of homozygosity (13.4 Mb and 10.6 Mb on
chromosomes 1 and 16, respectively) each contained a
candidate gene implicated in coenzyme Q10 biosynthesis:
CABC1 (also known as COQ8) on chromosome 1 and
COQ9 on chromosome 16.The AmDNA Sequence Analysis
The entire coding sequence of CABC1 was wild-type. A
homozygous C/T transition was identiﬁed in COQ9 at
position 730 of the cDNA c.730C/T (Figure 3), predicting
a premature stop codon, p.R244X, in exon 7, truncating
the terminal 75 amino acids of the protein. Parental DNA
Figure 2. HPLC Analysis of Coenzyme Q10 in Cultured Skin
Fibroblasts
Reverse phase EC-HPLC chromatograms obtained from lipid
extracts of cultured skin fibroblasts from (A) healthy control
fibroblasts and (B) the patient. Retention times are coenzyme
Q9 ¼ 10.45 min; coenzyme Q10 ¼ 14.15 min. The patient’s trace
clearly shows an additional peak at 13.22 min (arrow) not resulting
from coenzyme Q9 or coenzyme Q10, likely to be the result of
accumulation of a metabolic intermediate of coenzyme Q10
biosynthesis.
Table 3. Regions of Homozygosity Observed in the Patient
Chromosome Flanking SNPs
Length of
Homozygous
Region Mb
Candidate Genes
Located in Region
of Homozygosity
1 rs12043991, rs1009658 13.4 CABC1
2 rs6749901, rs3755021 5
3 rs9883258, rs7636942 3.2
3 rs1393555, rs9855944 10.1
5 rs4498289, rs294580 3.3
7 rs41943, rs17595350 2.3
8 rs7013926, rs6474040 6.6
12 rs4931594, rs10161491 1.5
13 rs1314940, rs2025736 15.7
16 rs7201926, rs36553 10.6 COQ9
17 rs11078078, rs7212579 16.8
17 rs2229611, rs6503398 1.8
19 rs4807140, rs2240669 2.4
19 rs1688021, rs10422365 2.9
20 rs6021247, rs6022204 1.5
22 rs136026, rs756638 4.9erican Journal of Human Genetics 84, 558–566, May 15, 2009 561
was not available for analysis. This mutation was absent in
308 control alleles, including 114 Pakistani control alleles.
The arginine at position 244 of the protein is highly
conserved through evolution (Figure 4). Sequence analysis
in 20 further patients with primary coenzyme Q10 deﬁ-
ciency without a genetic diagnosis did not reveal any
mutations in COQ9.
Reverse Transcriptase-PCR Analysis of COQ9
from Fibroblasts
COQ9 cDNA was successfully ampliﬁed from ﬁbroblasts
in three controls but could not be ampliﬁed from the
patient’s ﬁbroblasts, on three occasions with RNA from
two independent extractions (see Supplemental Data). In
both patient and controls, ampliﬁcation of the house-
keeping gene encoding the 60S ribosomal protein L19
was observed (Supplemental Data). This result is strongly
suggestive of the occurrence of nonsense-mediated decay
of COQ9 mRNA in the patient. Consequently it is likely
that a negligible amount of COQ9 protein will be formed.
Figure 3. Sequence Analysis of COQ9
Sequencing electropherograms showing homozygous c.730C/T
mutation in the patient’s genomic DNA (top) and healthy control
genomic DNA (bottom). The mutation predicts a change from argi-
nine to a stop codon at amino acid 244 of the protein.Modeling of COQ9 Structure
Models for 12 alternative template/alignment conforma-
tions were generated and evaluated with two quality
assessments as described in Subjects and Methods. On
the basis that the template structures were homodimeric,
we also assessed both monomeric and homodimeric
models. The homodimer models were consistently found
to score better by the quality assessment methods than
did the monomers because the monomer would expose
a considerable hydrophobic surface area that is buried in
the interface in the dimer model (Figure 5).
Yeast Studies
The Dcoq9 yeast mutant failed to grow on respiratory
medium (Figure 6A) as expected. Transformation of the
Dcoq9 yeast mutant with yeast COQ9 inserted into a multi-
copy yeast expression vector under the control of a consti-
tutive promoter restored respiratory growth to wild-type
levels (Figure 6B). Overexpression of human COQ9 with
the same vector and promoter did not restore respiratory
growth in the yeast Dcoq9 mutant (Figure 6D). However,
the introduction of a stop mutation by site-directed muta-
genesis at the equivalent position of the human mutation
(human p.R244X ¼ yeast p.K191X) into the cloned yeast
COQ9 abolished respiratory growth (Figure 6C).
Discussion
We used a strategy involving search for homozygosity by
descent at loci of candidate genes known to be involved
in coenzyme Q10 biosynthesis to identify the causative
genetic defect in a patient with neonatal presentation of
primary coenzyme Q10 deﬁciency. Although the parents
of our patient were not known to be related, there is some
evidence that extended regions of homozygosity can occur
in outbred individuals.31–33We also reasoned that homozy-
gosity by descent is more likely to be the cause of an
extremely rare disorder such as primary coenzymeQ10 deﬁ-
ciency (observed in only 2 of more than 1000 pediatric
muscle biopsies from patients with suspected mitochon-
drial disorders analyzed by our biochemistry laboratory).
In fact, the amount of homozygosity in the patient suggests
that the parents may have a greater degree of relationship
than was elicited in the clinical history.
Biosynthesis of coenzyme Q10 is a complex biological
process that is not completely understood in humans. AFigure 4. Evolutionary Conservation Data for COQ9
562 The American Journal of Human Genetics 84, 558–566, May 15, 2009
numberofproteins involved inbiosynthesis of coenzymeQ
in yeast and other lower organisms have been characterized
by studies of respiratory-deﬁcient mutants, and the human
homologs of 16 of these proteins have been identiﬁed
(Table 1). The exact function of several of these proteins
remains unknown, but four have been implicated in
primary deﬁciency of coenzyme Q10 in humans (Table 4).
Clinical features of patients with mutations in these genes
are summarized in Table 4. The different clinical phenotype
of our patient, and the observation of an extra peak with
a slightly shorter retention time than coenzyme Q10 on
HPLC analysis, led us to hypothesize that our patient had
a different genetic basis to other patients reported in the
literature, and that this was likely to be a distal step of coen-
zyme Q10 biosynthesis, possibly in modiﬁcation of the
4-hydroxybenzoate ring.
Our report conﬁrms that COQ9 is necessary for the
biosynthesis of coenzyme Q10 in humans and that its
deﬁciency is associated with an early onset and severe
multisystem disorder. Evidence for pathogenicity of the
mutation observed in this patient are that it is a nonsense
Figure 5. Molecular Model of COQ9 in Homodimeric Form
One monomer is depicted in red, the other in blue. Figure created
with Pymol.42
Figure 6. Yeast Studies
Left: Growth on respiratory (glycerol) medium. Right: Growth on
fermentable (glucose) medium selective for the plasmids. (a)
Dcoq9 mutantþ empty plasmid; (b) Dcoq9 mutantþ pYcoq9 (yeast
COQ9); (c) Dcoq9 mutantþ pYcoq9Stop (yeast coq9 K191X); (d)
Dcoq9 mutantþ pHcoq9 (human COQ9). COQ9 genes were placed
under the control of a constitutive promoter on a multicopy
plasmid.The Ammutation, leading to nonsense-mediated decay of the
mRNA, and its absence in >300 control chromosomes.
Supportive evidence is provided by the yeast studies,
which demonstrated a respiratory defect in yeast in which
the equivalent portion of the Coq9 protein had been
deleted by site-directed mutagenesis.
The model proposed for the structure depends partly on
the quaternary state, because otherwise the conformation
of the C-terminal region would not make sense without
signiﬁcant repacking in order to prevent exposure of signif-
icant hydrophobic surface area. Although the true quater-
nary structure is unknown, it has previously been reported
that the yeast ortholog of this protein is a homo-olig-
omer.34 Although the authors state that the mass of the
native complex is some three times the mass of the mono-
meric form, this could be accounted for by complexation
with another protein.
The precise function of COQ9 remains obscure. Yeast
Coq9p has been localized to the inner mitochondrial
membrane, facing the matrix.34 Studies of yeast Coq9p
showed that it cosediments with other proteins involved in
coenzyme Q biosynthesis, including Coq3p and Coq5p,34
leading some authors to suggest that Coq9p is part of a
multienzyme coenzyme Q biosynthetic complex.35 COQ9
mutants in yeast incorporate 4-hydroxybenzoic acid into
3-hexaprenyl-4-hydroxybenzoic acid, indicating that the
COQ9product acts distally to prenylationof 4-hydroxyben-
zoic acid.34 Our ﬁndings support this suggestion and indi-
cate that COQ9 is likely to be involved in an enzymatic
modiﬁcation step of the benzoquinone ring, because of
the observation of an extra peak on HPLC analysis of our
patient’s ﬁbroblasts. We hypothesize that this extra peak
represents an accumulating biosynthetic intermediate.
Yeast COQ9 mutants can be suppressed by the overex-
pression of COQ8, suggesting a genetic or physical interac-
tion of these two genes or their products.34 For example, it
has been suggested that the yeast Coq9 polypeptide might
be the substrate of the putative kinase ABC1/COQ8.35
The human homolog of ABC1/COQ8 is CABC1 and was
recently demonstrated to bemutated in primary coenzyme
Q10 deﬁciency presenting with childhood-onset cerebellar
ataxia, with additional features including exercise intoler-
ance and seizures.17,18 The clinical phenotype and disease
progression associated with CABC1 mutations appears
to be much milder than that observed in our patient
with COQ9 mutations, providing evidence that these two
proteins are likely to have quite distinct functions.
Although it is interesting that cerebellar atrophy is shared
by patients with mutations in CABC1 and our patient with
COQ9 mutations, ataxia appears to be common to several
forms of coenzyme Q10 deﬁciency, both primary and
secondary.2,4,6,7,19,36,37 This may simply reﬂect low endo-
genous coenzyme Q10 levels in the cerebellum, leading to
increased susceptibility of this tissue to damage in condi-
tions of inherited or acquired coenzyme Q10 deﬁciency.
38
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Table 4. Genotype-Phenotype Correlation in Inherited Deficiency of Coenzyme Q10 Biosynthesis
Gene
Number of
Patients
(Families)
Age at
Onset Clinical Features MRI Features
Lactate mmol/l
(Reference Range)
Coenzyme
Q10 Level
(Reference
Range)
Response to
Exogenous Q10
Supplementation References
PDSS1 2 (1) 1–2 y deafness, bulimia,
obesity, optic
atrophy,
valvulopathy,
macrocephaly,
peripheral
neuropathy, MR
NR B 2.1 at 22 y; 3.2
at 14 y (1.0–1.55)
Fb 4 pmol/mg
(1205 32)
alive at 22 y
(mild MR)
15
PDSS2 1 3 mo Leigh syndrome,
nephropathy
bilateral
symmetrical T2
hyperintensity
in BG
B 7.5 (<2.0) M 4.6 ng/mg
(32.15 6.8);
Fb 6.7 ng/mg
(52.25 9.1)
no clinical response;
died at 8 mo
(refractory status
epilepticus)
13
COQ2 2 (1) 9–12 mo encephalomyopathy,
nephropathy
cerebellar atrophy
and stroke-like
lesions
B þ CSF N M 12 ng/mg
(32.15 6.7);
Fb 18–19 ng/mg
(1055 14)
dramatic
improvement
of neurological
manifestations;
renal transplant at
3 y in proband; renal
disease responded
to early treatment
in younger sibling
14,22
COQ2 2 (2) 18 mo steroid-resistant
nephropathy
N B N M 12 pmol/mg
(17.6–49.2); KC
4.5 pmol/mg
(26–180)
neurologically
normal during 8 mo
of treatment
16
5 d acute renal failure,
progressive epileptic
encephalopathy
cortical and
subcortical stroke-
like lesions
CSF 11.8 (1.1–2.4) M 0.8 pmol/mg
(17.6–49.2); KC
3.7 pmol/mg
(26–180)
no clinical response;
died at 6 mo
(respiratory failure).
COQ2 1 birth neurological
distress, liver failure,
nephrotic syndrome,
anemia,
pancytopaenia,
IDDM, seizures
NR B 22.7 (1.0–1.55) Fb 29 pmol/mg
(1205 32)
no clinical response;
died at 12 d
(multiorgan failure)
15
CABC1 2 (2) <18 mo proximal muscle
weakness, cerebellar
ataxia, strabismus,
ptosis, seizures
cerebellar atrophy
and posterior
cerebral cortical
and subcortical
hyperintensities
(both patients)
B 3.0 (1.0–1.55);
CSF 4.0 (<2.0)
M 2.6–9.4 pmol/mg
(32.25 9.8);
Fb 125 pmol/mg
(1205 32)
severe neurological
deterioration and
EPC (alive at 16 y
and 14 y)
17
CABC1 7 (4) 3–11 y cerebellar ataxia,
exercise intolerance
cerebellar atrophy B N – 7.8 (0.5–2.2) M 12.6 ng/mg
(n¼ 1) (27.65 4.4);
Fb 29–69 ng/mg
(n¼ 3)
(58.55 4.1)
mild improvement
of ataxia (only one
patient treated)
18
COQ9 1 birth neonatal lactic
acidosis, seizures,
global
developmental
delay, hypertrophic
cardiomyopathy,
renal tubular
dysfunction
cerebral þ
cerebellar
atrophy
B 19.4 (0.9–1.9) M 37 pmol/mg
(140–580); Fb
25.3 pmol/mg
(39–75)
no clinical response;
died at 2 y
5; this
report
Abbreviations: B, blood; BG, basal ganglia; CSF, cerebrospinal fluid; d, days; EPC, epilepsia partialis continua; Fb, fibroblast; IDDM, insulin-dependent dia-
betes mellitus; KC, kidney cortex; M, muscle; mo, months; MR, mental retardation; N, normal; NR, not reported; y, years.but include reduced ATP production, increased production
of reactive oxygen species, and impaired de novo pyrimi-
dine biosynthesis.39,40 A recent report has suggested that564 The American Journal of Human Genetics 84, 558–566, May 15early treatment is associated with an excellent prognosis
in childhood-onset primary coenzyme Q10 deﬁciency.
22
The lack of response to coenzymeQ10 replacement therapy, 2009
11
1
1
1
1
1
1
1in our patient is most likely explained by the presence of
irreversible disease manifestations (such as cerebral and
cerebellar atrophy) by the time the diagnosis was estab-
lished. Other possible explanations include inadequate
transfer of exogenous coenzymeQ10 across the blood-brain
barrier, variable bioavailability of different coenzyme Q10
formulations,41 and variations between individuals in
coenzyme Q10 absorption and/or intramitochondrial
uptake of exogenous coenzyme Q10.
In conclusion, characterization of disorders of coenzyme
Q10 isofparamount importancebecause theyarepotentially
treatable. We report a new genetic cause of primary coen-
zymeQ10deﬁciency. Identiﬁcationofmutations responsible
for coenzyme Q10 deﬁciency allows the possibility of
prenatal diagnosis and treatment from birth, which could
improve the clinical outcome.
Supplemental Data
Supplemental Data include one ﬁgure and one table and can be
found with this article online at http://www.ajhg.org/.
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